Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.3 USD | +0.10% | +73.05% | +56.85% |
12:13pm | North American Morning Briefing : Traders Wait for -2- | DJ |
04-30 | Barclays Upgrades Deciphera Pharmaceuticals to Equalweight From Underweight, Price Target is $26 | MT |
Business Summary
Number of employees: 355
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Switch Control Kinase Inhibitor Platform
100.0
%
| 126 | 100.0 % | 159 | 100.0 % | +26.75% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
76.4
%
| 97 | 77.5 % | 122 | 76.4 % | +25.03% |
Rest of World
12.3
%
| 14 | 11.1 % | 20 | 12.3 % | +39.91% |
Germany
11.3
%
| 14 | 11.4 % | 18 | 11.3 % | +25.58% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Steven Hoerter
CEO | Chief Executive Officer | 53 | 16/05/18 |
Tucker Kelly
DFI | Director of Finance/CFO | 53 | 31/01/15 |
Kevin Brodbeck
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/22 |
Chief Tech/Sci/R&D Officer | - | 31/12/16 | |
Dashyant Dhanak
CTO | Chief Tech/Sci/R&D Officer | 63 | 04/09/23 |
Matthew Sherman
CTO | Chief Tech/Sci/R&D Officer | 68 | 01/10/19 |
Lisa Amaya Price
HRO | Human Resources Officer | - | 31/12/21 |
Kelley Dealhoy
PRN | Corporate Officer/Principal | - | 15/06/22 |
Jama Pitman
PRN | Corporate Officer/Principal | 45 | 31/12/14 |
Daniel Martin
PRN | Corporate Officer/Principal | 49 | 17/09/18 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Patricia Allen
BRD | Director/Board Member | 62 | 31/08/16 |
Edward Benz
BRD | Director/Board Member | 78 | 30/06/19 |
Ron Squarer
CHM | Chairman | 57 | 03/12/19 |
John R. Martin
BRD | Director/Board Member | 63 | 31/01/15 |
James Bristol
BRD | Director/Board Member | 77 | 31/07/07 |
Susan Kelley
BRD | Director/Board Member | 69 | 07/07/19 |
Steven Hoerter
CEO | Chief Executive Officer | 53 | 16/05/18 |
Dennis Walsh
BRD | Director/Board Member | 56 | 31/01/15 |
Director/Board Member | 66 | 31/10/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 82,225,972 | 57,541,331 ( 69.98 %) | 0 | 69.98 % |
Company contact information
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+56.85% | 2.08B | |
-3.05% | 102B | |
+1.51% | 96.09B | |
+2.13% | 22.28B | |
-16.86% | 21.4B | |
-9.05% | 18.14B | |
-39.98% | 17.02B | |
-14.17% | 16.09B | |
+6.56% | 13.83B | |
+33.32% | 11.97B |
- Stock Market
- Equities
- DCPH Stock
- Company Deciphera Pharmaceuticals, Inc.